APA (7th ed.) Citation

L, S., D, R., A, B., N, B., E, R., & P, F. (2022). A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. The Journal of dermatological treatment, 33(1), 329. https://doi.org/10.1080/09546634.2020.1752888

Chicago Style (17th ed.) Citation

L, Spelman, Rubel D, Brnabic A, Burkhardt N, Riedl E, and Foley P. "A Subset Analysis of Efficacy and Safety Outcomes from Phase 3 Clinical Studies of Ixekizumab for the Treatment of Patients with Severe Plaque Psoriasis." The Journal of Dermatological Treatment 33, no. 1 (2022): 329. https://doi.org/10.1080/09546634.2020.1752888.

MLA (9th ed.) Citation

L, Spelman, et al. "A Subset Analysis of Efficacy and Safety Outcomes from Phase 3 Clinical Studies of Ixekizumab for the Treatment of Patients with Severe Plaque Psoriasis." The Journal of Dermatological Treatment, vol. 33, no. 1, 2022, p. 329, https://doi.org/10.1080/09546634.2020.1752888.